This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Interpreting ANA results

Authoring team

The type and nature of autoantibody testing and the way results are reported varies between local laboratories.

The most useful ANA result is a negative test as this makes it unlikely that the subject has an autoimmune connective tissue disease.

Other ANA results are often expressed as a maximum dilution titre, though some ELISA assays may give results in international units(IU).

  • a titre in the range of 1:40-1:80 is usually reported as a positive test, though patients rarely have active autoimmune disease and interpretation of the result relies heavily upon the clinical situation
    • if however a patient is complaining of a photosensitive rash/or arthritis and is found to have an ANA of 1:80, that result is likely to be highly significant (1)
  • a titre greater than 1:160, however is more likely to be significant and one may then go on to explore dsDNA or ENA tests.

A significantly positive ANA, in the absence of clinical evidence of connective tissue disease does not mean disease is present, though a proportion of these individuals may later develop an autoimmune syndrome.

Reference:

  1. Pulse (2004), 64 (2), 63.

 

 


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.